Xarelto Lawsuit Update: Kristine Kraft of Schlichter, Bogard & Denton, LLP Reports on Study Finding Bleeds Difficult to Stop for Some Anticoagulants, Including Xarelto - San Diego, California Talk Radio Station - AM 760 KFMB

Xarelto Lawsuit Update: Kristine Kraft of Schlichter, Bogard & Denton, LLP Reports on Study Finding Bleeds Difficult to Stop for Some Anticoagulants, Including Xarelto

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, reports on the findings of a new study published in the Journal of Neurosurgery regarding the increased difficulties of stopping bleeding events for patients using certain direct Factor Xa inhibitor medications, including Xarelto®. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have suffered serious bleeding events after using Xarelto®.

St. Louis, MO (PRWEB) August 26, 2014

A new study published in the August issue of the Journal of Neurosurgery found that internal bleeding associated with certain anticoagulants - including Xarelto® - is more difficult to stop in comparison to other blood thinning medications. The study discussed new guidelines on how to treat uncontrolled bleeding in the brain and pointed out that surgeons are faced with an extreme difficulty of treating brain hemorrhage patients who are taking certain direct Factor Xa inhibitor anticoagulant medications, such as Xarelto®. The study authors emphasize that when a patient suffers a bleed while taking warfarin, another blood thinning medication, the bleeding can be reversed by quickly administering vitamin K; however, direct Factor Xa inhibitors such as Xarelto® are within a newer class of anticoagulants that do not have a reversal agent.

We continue to hear from individuals who allege to have experienced life-threatening and serious injuries after using Xarelto, says Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP. She adds, We will fight for the rights of individuals who allege to have experienced serious and life-threatening injuries after using Xarelto® and our office is offering free and confidential case reviews to those who allege to have suffered injuries.

The anti-clotting medication Xarelto®, which is marketed by Johnson & Johnson in the United States and by Bayer outside the United States, was approved by the Food and Drug Administration (FDA) in July 2011 for use in patients who recently underwent hip or knee replacement surgery to reduce the risk of blood clots. Use of the drug was later extended by the FDA for patients with atrial fibrillation (AF) to reduce the risk of stroke and for the general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

According to the Institute for Safe Medication Practices (ISMP) most recent Quarter Watch Report compiling data from 2013, Xarelto® (rivaroxaban) has overtaken Pradaxa® (dabigatran) in the number of reported adverse events, including serious bleeding events. The ISMP QuarterWatch reports that in 2013, the U.S. Food and Drug Administration (FDA) reported receiving 680 serious adverse event reports from individuals who alleged to have suffered adverse events while taking the anticoagulant drug Xarelto® (rivaroxaban), while only 528 serious adverse events were reported for Pradaxa® (dabigatran). The FDAs Adverse Event Reporting System (FAERS) remains the cornerstone of postmarket safety surveillance, the mechanism through which most significant drug risks are detected once a drug has been approved and is available on the market.

About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications, unsafe medical devices and toxic torts, including but not limited to: In re: Testosterone Replacement Therapy Products Liability Litigation (MDL 2545, Case No. 14-md-2545, N.D. Ill.), In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385, Case No. 12-md-2385, S.D. Ill.), In re: E.I. Du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL 2433, Case No. 13-md-2433, S.D. Ohio), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100, Case No. 09-md-2100, S.D. Ill.), In re: NuvaRing® Products Liability Litigation (MDL 1964, Case No. 08-md-1964, E.D. Mo.), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909, Case No. 08-md-50000, N.D. Ohio), and In re: Ortho Evra® Products Liability Litigation (MDL 1742, Case No. 06-md-40000, N.D. Ohio).

The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton, LLP aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.

If you or a loved one has suffered serious injuries after using Xarelto®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. We are available to either handle these cases or work as co-counsel, so other attorneys with these types of cases are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12120243.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Midwest Television, Inc. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.